STEP Perspective - 2000Important note: Information in this article was accurate in April 2000. The state of the art may have changed since the publication date.
Click here to return to STEP Perspective main menu

Update: Twice-daily Nelfinavir

STEP Perspective, Volume 00, No. 1 Spring 2000


In November 1999, the FDA approved twice-daily dosing of the protease inhibitor Nelfinavir (Viracept). Instead of 750mg three times daily, one can take 1,250mg twice daily. This eliminates that middle-of-the-day dose so often overlooked and dovetails with such other drugs commonly taken twice-daily as Combivir, 3TC, ddI and d4T.

20000401
STEP2000-0402


Copyright © 2000 - Seattle Treatment Education Project, 1123 East John Street, Seattle, WA 98102. (206) 329-4857 or (877) 597-STEP [7837] (toll-free, valid only in the Pacific Northwest: Washington, Oregon, Idaho, Alaska, and Montana) e-mail: step100@aol.com

ÆGiS is made possible through unrestricted grants from Roxane Laboratories, Inc., iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

ÆGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1985, 2000. ÆGiS & the Sisters of Saint Elizabeth of Hungary. All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGIS and the Sisters of Saint. Elizabeth of Hungary, or the party credited as the provider of the content.